Rourkela: In its effort to bring innovations from the lab to the real world, the National Institute of Technology Rourkela (NIT Rourkela) spun off the startup Miraqules MedSolutions Pvt. Ltd. On Tuesday, the startup received regulatory approval for commercial manufacturing and clinical deployment of its patented technology—a rapid nano-biopolymer hemostat designed to transform emergency hemorrhage control.
As India faces significant challenges in trauma care, a major proportion of road accident fatalities occur due to delays in controlling patients’ bleeding. Many of these incidents take place in remote or rural areas where trauma care is not readily available. The technology developed at NIT Rourkela can bridge this gap and help reduce preventable casualties.
StopBleed, the technology developed at NIT Rourkela, has received approval from the Central Drugs Standard Control Organisation (CDSCO) as a Class C medical device, marking a significant step in translating academic research into life-saving medical technology. The product enables rapid control of severe bleeding arising from road accidents, gunshot wounds, blast injuries, industrial accidents, deep stab wounds, and other critical or life-threatening trauma situations.
The innovation is an advanced bleeding control solution available in powder and pellet forms, designed for use in trauma situations such as road accidents, military injuries, and emergency first-aid scenarios. With a shelf life of three years at room temperature, it can be easily used by medical professionals as well as non-medical first-aid responders, making it suitable for emergencies and potentially saving lives. Developed using nanofibrous aggregate technology, the product rapidly absorbs blood plasma while trapping blood cells within a high-surface-area fibrous mesh. This accelerates the body’s natural clotting mechanisms and forms a strong hydrogel seal at the wound.
The technology was originally patented by the Institute and developed in the Department of Biotechnology and Medical Engineering by Professor Devendra Verma and his research graduate Sabir Hussain. Subsequently, the technology was transferred to Miraqules MedSolutions Pvt. Ltd., led by Hussain, for manufacturing, distribution, and field deployment.
On this achievement, Prof. K. Umamaheshwar Rao, Director of NIT Rourkela, congratulated the innovators and stated that the product has the potential to strengthen emergency healthcare systems.
Speaking about bringing the technology from his lab to real-world application, Prof. Devendra Verma, Associate Professor and HOD of Biotechnology and Medical Engineering at NIT Rourkela, said,
“Seeing StopBleed progress from our laboratory at NIT Rourkela to CDSCO-approved real-world use is truly fulfilling. It has the potential to help first responders control hemorrhage quickly and save lives during trauma, whether in military settings or rural emergencies across India. I also hope this milestone encourages more students to embrace entrepreneurship and translate strong research into deployable healthcare solutions. India needs more healthcare startups to reduce import dependence, lower costs, and develop context-specific technologies.”
In compliance with international safety standards (ISO 10993) and USFDA guidelines, Team Miraqules has conducted multiple laboratory and animal tests of the innovation and achieved satisfactory results. It has also been tested in a real-life clinical setting through a first-in-human study conducted in collaboration with the Sanjay Gandhi Institute of Trauma and Orthopedics, Bangalore.
Speaking about the commercial rollout, NIT Rourkela alumnus Sabir Hossain (Founder & CEO, Miraqules MedSolutions Pvt. Ltd.) said,
“The CDSCO approval validates our years of scientific work and confirms our assumptions regarding the product–market fit for StopBleed. We have now initiated limited deployment across select clinical settings to gather feedback on its acceptability as a standard of care for managing external bleeding. In parallel, we are actively exploring strategic partnerships for distribution to ensure that this life-saving innovation can be rapidly scaled and made accessible across India’s emergency care ecosystem.”
Aligned with the Government of India’s Make-in-India vision, StopBleed is expected to transform trauma care and the approach of medical facilities toward rapid bleeding control and emergency response management across the country.
